HIV/AIDS and homelessness, part 2: Treatment issues

AIDS Reader

Volumn 15, Issue 11, 2005, Pages

  Douaihy, Antoine B ^a   Stowell, Keith R ^c   Bui, Thuy ^a   Daley, Dennis ^b   Salloum, Ihsan ^b  

^a Department of Psychiatry ^*

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Adherence; HIV AIDS; Homelessness; Integrated care; Substance abuse

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; BUPRENORPHINE; EFAVIRENZ; METHADONE; NEVIRAPINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION COMPLICATION; MEDICAL SPECIALIST; MENTAL HEALTH; OPIATE ADDICTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; POPULATION RISK; REVIEW; RISK FACTOR; SUBSTANCE ABUSE; ADDICTION; ADOLESCENT; CHILD; FEMALE; HOUSING; INTEGRATED HEALTH CARE SYSTEM; MALE; MENTAL DISEASE; METHODOLOGY;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; DELIVERY OF HEALTH CARE, INTEGRATED; FEMALE; HIV INFECTIONS; HOMELESS PERSONS; HOUSING; HUMANS; MALE; MENTAL DISORDERS; PATIENT COMPLIANCE; SUBSTANCE-RELATED DISORDERS;

EID: 33644656496     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Brickner PW, McAdam JM, Torres RA. Providing health services for the homeless: a stitch in time. Bull N Y Acad Med. 1993;70:146-170.
2. Schambelan M, Grunfeld C. Endocrinologic manifestations of HIV infection. In: Sande MA, Volberding PA, eds. The Medical Management of AIDS. Philadelphia: WB Saunders Co; 1995.
3. Wheeler DA, Gilbert CL, Launer CA, et al. Weight loss as a predictor of survival and disease progression in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:80-85.
4. Wright JD, Weber E. Homelessness and Health. New York: McGraw-Hill; 1997.
5. Gelberg L, Linn LS. Assessing the physical health of homeless adults [published correction appears in JAMA. 1989;262:3132]. JAMA. 1989;262:1973-1979.
6. White MC, Tulsky JP, Dawson C, et al. Association between time homeless and perceived health status among the homeless of San Francisco. J Community Health. 1997;22;271-282.
7. Klinkenberg WD, Caslyn RJ, Morse GA, et al. Prevalence of human immunodeficiency virus, hepatitis B, and hepatitis C among homeless persons with co-occurring severe mental illness and substance use disorders. Compr Psychiatry. 2003;44:292-302.
8. Nyamathi AM, Dixon EL, Robbins W, et al. Risk factors of hepatitis C virus infection among homeless adults. J Gen Intern Med. 2002;17:134-143.
9. HCH Clinicians' Network. Eliciting behavioral change: tools for HCH clinicians. Healing Hands. 2000;4:1-4.
10. Torres RA, Mani S, Altholz J, Brickner PW. Human immunodeficiency virus infection among homeless men in a New York City shelter. Association with Mycobacterium tuberculosis infection. Arch Intern Med. 1990;150:2030-2036.
11. Zolopa AR, Hahn JA, Gorter R, et al. HIV and tuberculosis infection in San Francisco's homeless adults. JAMA. 1994;272:455-461.
12. Haddad MB, Wilson TW, Ijaz K, et al. Tuberculosis and homelessness in the United States, 1994-2003. JAMA. 2005;293:2762-2766.
13. Saez H, Valencia E, Conover S, et al. Tuberculosis and HIV among mentally ill men in a New York City shelter. Am J Public Health. 1996;86:1318-1319.
14. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998;280:78-86.
15. Deeks SG, Smith M, Holodniy M. HIV-1 protease inhibitors: a review for clinicians. JAMA. 1997;277: 145-153.
16. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in care of HIV-infected adults in the United States: results from the HIV cost and services utilization study. JAMA. 1999;281:2305-2315.
17. Sorvillo F, Kerndt P, Odem S, et al. Use of protease inhibitors among persons with AIDS in Los Angeles County. AIDS Care. 1999;11:147-155.
18. Bogart LM, Kelly JA, Catz SL. Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr. 2000;23:396-404.
19. Graham NM, Jacobson LP, Kuo V, et al. Access to therapy in the Multicenter AIDS Cohort Study, 1989-1992. J Clin Epidemiol. 1994;47:1003-1012.
20. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15: 1707-1715.
21. Solomon L, Vlahov D, Astemborski J, et al. Factors associated with initiation of zidovudine in a cohort of injection drug users. J Drug Issues. 1995;25: 225-233.
22. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547-549.
23. Weiss L, Fluger M, McCoy K. Health Care Accessibility and Acceptability Among People That Inject Drugs or Use Crack Cocaine: A Report Prepared by the Office of Special Populations. New York: The New York Academy of Medicine; 2000.
24. Fairfield KM, Libman H, Davis RB, et al. Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999;14:395-401.
25. Riley ED, Wu AW, Perry S, et al. Depression and drug use impact health status among marginally housed HIV-infected individuals. AIDS Patient Care STDS. 2003;17:401-i06.
26. Celentano DD, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544-546.
27. Riley ED, Bangsberg DR, Guzman D, et al. Antiretroviral therapy, hepatitis C virus, and AIDS mortality among San Francisco's homeless and marginally housed. J Acquir Immune Defic Syndr. 2005;38: 191-195.
28. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756-765.
29. Lebow J, Retondo M, Samet JH, et al. Initial presentation of HIV-infected homeless persons for primary medical care. Presented at the VIII International AIDS Conference; July 19-24, 1992; Amsterdam. Abstract PoD 5734.
30. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994; 330:763-768.
31. Baker J. Strategies to maximize adherence: a holistic approach. Presented at the Closing the Gap Summit 2005; March 2-3, 2005; Orlando, Fla.
32. Miller LG, Liu H, Hays RD, et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med. 2002;17:1-11.
33. Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26:435-442.
34. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366.
35. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181-1183.
36. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-347.
37. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002;29(suppl 1): S2-S10.
38. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2001;31(suppl 3): S123-S127.
39. Lucas GM, Cheever LW, Chaisson ER, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;71:251-259.
40. Avants SK, Margolin A, Warburton LA, et al. Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. Am J Addict. 2001;10:69-78.
41. Clarke S, Delamere S, McCullough L, et al. Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users. HIV Med. 2003;4:3337.
42. Lewis JR, Boyle DP, Lewis LS, et al. Reducing AIDS and substance abuse risk factors among homeless, HIV-infected, drug-using persons. Res Soc Work Pract. 2000;10:15-33.
43. Sing N, Squier C, Sivek C, et al. Determinants of compliance with antiretroviral therapy in patient with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261-269.
44. Treisman GJ, Angelino AF, Hutton HE. Psychiatric issues in the management of patients with HIV infection. JAMA. 2001;286:2857-2864.
45. Chesney MA. New Antiretroviral Therapies: Adherence Challenges and Strategies. Philadelphia: Health Communications Group; 1998.
46. Muma RD, Ross MW, Parcel GS, et al. Zidovudine adherence among individuals with HIV infection. AIDS Care. 1995;7:439-447.
47. Ingersoll K. The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care. 2004;16:199-211.
48. Broadhead RS, Heckathorn DD, Altice FL, et al. Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study. Soc Sci Med. 2002;55:235-246.
49. Altice FL, Mezger JA, Hodges J. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. Clin Infect Dis. 2004:38(suppl 5): S376-S387.
50. Adamian MS, Golin CE, Shain LS, De Vellis B. Brief motivational interviewing to improve adherence to antiretroviral therapy: development and qualitative pilot assessment of an intervention. AIDS Patient Care STDS. 2004;18:229-238.
51. Castello-Branco LR, Linhares-Carvalho MI, Ponce de Leon AC. AIDS therapy in Brazil. Nature. 1998;392:431.
52. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977-1983.
53. Stone VE, Mauch MY, Steger K, et al. Race, gender, drug use, and participation in AIDS clinical trials. J Gen Intern Med. 1997;12:150-157.
54. Eldred LJ, Wu AW, Chaisson RE, et al. Adherence to antiretroviral and Pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:117-125.
55. Stone VE, Clarke J, Lovell J, et al. HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med. 1998;13: 586-593.
56. Cunningham WE, Andersen RM, Katz MH, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the Unites States. Med Care. 1999;37:1270-1281.
57. Shelton D, Marconi K, Pounds M. Issues related to health care utilization and medical adherence among prenatal HIV seropositive African-American women in Miami: the role of the family and the extended kinship network. Fam Syst Med. 1993;11:1-14.
58. Rotherman-Borus MJ, Koopman C, Ehrhardt AA. Homeless youths and HIV infection. Am Psychol. 1991;46:1188-1197.
59. Kral AH, Molnar BE, Booth RE, Watters JK. Prevalence of sexual risk behaviour and substance use among runaway and homeless adolescents in San Francisco, Denver and New York City. Int J STD AIDS. 1997;8:109-117.
60. Cochran BN, Stewart AJ, Ginzler JA, et al. Challenges faced by homeless sexual miniorities: comparison of gay, lesbian, bisexual, and transgender homeless adolescents with their heterosexual counterparts. Am J Public Health. 2002;92:773-777.
61. Clements K. The San Francisco Transgender Health Project. Presented at the Transgender Care Conference; May 5, 2000; San Francisco. Available at: http://hivinsite.ucsf.edu/InSite.jsp?doc=2098.473a.